KR101398264B1 - Ｐ２ｘ７­수용체 길항제로서의 치환된 ｎ­페닐메틸­５­옥소­프롤린­２­아미드 및 그의 사용 방법 - Google Patents

Ｐ２ｘ７­수용체 길항제로서의 치환된 ｎ­페닐메틸­５­옥소­프롤린­２­아미드 및 그의 사용 방법 Download PDF

Info

Publication number
KR101398264B1
KR101398264B1 KR1020097002352A KR20097002352A KR101398264B1 KR 101398264 B1 KR101398264 B1 KR 101398264B1 KR 1020097002352 A KR1020097002352 A KR 1020097002352A KR 20097002352 A KR20097002352 A KR 20097002352A KR 101398264 B1 KR101398264 B1 KR 101398264B1
Authority
KR
South Korea
Prior art keywords
mmol
methyl
mixture
give
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097002352A
Other languages
English (en)
Korean (ko)
Other versions
KR20090028808A (ko
Inventor
라우라 제이 챔버스
로버트 글리브
스테판 셍거
다릴 시몬 월터
Original Assignee
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0613473A external-priority patent/GB0613473D0/en
Priority claimed from GB0622825A external-priority patent/GB0622825D0/en
Priority claimed from GB0705263A external-priority patent/GB0705263D0/en
Priority claimed from GB0711439A external-priority patent/GB0711439D0/en
Application filed by 글락소 그룹 리미티드 filed Critical 글락소 그룹 리미티드
Publication of KR20090028808A publication Critical patent/KR20090028808A/ko
Application granted granted Critical
Publication of KR101398264B1 publication Critical patent/KR101398264B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020097002352A 2006-07-06 2007-07-03 Ｐ２ｘ７­수용체 길항제로서의 치환된 ｎ­페닐메틸­５­옥소­프롤린­２­아미드 및 그의 사용 방법 Expired - Fee Related KR101398264B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0613473.8 2006-07-06
GB0613473A GB0613473D0 (en) 2006-07-06 2006-07-06 Novel compounds
GB0622825.8 2006-11-15
GB0622825A GB0622825D0 (en) 2006-11-15 2006-11-15 Novel compounds
GB0705263A GB0705263D0 (en) 2007-03-19 2007-03-19 Novel compounds
GB0705263.2 2007-03-19
GB0711439A GB0711439D0 (en) 2007-06-13 2007-06-13 Novel receptor antagonists and their methods of use
GB0711439.0 2007-06-13
PCT/EP2007/056675 WO2008003697A1 (en) 2006-07-06 2007-07-03 Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020147001116A Division KR20140016431A (ko) 2006-07-06 2007-07-03 Ｐ２ｘ７­수용체 길항제로서의 치환된 ｎ­페닐메틸­５­옥소­프롤린­２­아미드 및 그의 사용 방법

Publications (2)

Publication Number Publication Date
KR20090028808A KR20090028808A (ko) 2009-03-19
KR101398264B1 true KR101398264B1 (ko) 2014-05-26

Family

ID=38508907

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097002352A Expired - Fee Related KR101398264B1 (ko) 2006-07-06 2007-07-03 Ｐ２ｘ７­수용체 길항제로서의 치환된 ｎ­페닐메틸­５­옥소­프롤린­２­아미드 및 그의 사용 방법
KR1020147001116A Ceased KR20140016431A (ko) 2006-07-06 2007-07-03 Ｐ２ｘ７­수용체 길항제로서의 치환된 ｎ­페닐메틸­５­옥소­프롤린­２­아미드 및 그의 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147001116A Ceased KR20140016431A (ko) 2006-07-06 2007-07-03 Ｐ２ｘ７­수용체 길항제로서의 치환된 ｎ­페닐메틸­５­옥소­프롤린­２­아미드 및 그의 사용 방법

Country Status (25)

Country Link
US (2) US7718693B2 (enExample)
EP (1) EP2049478B1 (enExample)
JP (1) JP5283620B2 (enExample)
KR (2) KR101398264B1 (enExample)
AR (1) AR061815A1 (enExample)
AU (1) AU2007271182B2 (enExample)
BR (1) BRPI0714062A2 (enExample)
CA (1) CA2655675A1 (enExample)
CR (2) CR10545A (enExample)
CY (1) CY1113415T1 (enExample)
DK (1) DK2049478T3 (enExample)
EA (1) EA016076B1 (enExample)
ES (1) ES2385505T3 (enExample)
HR (1) HRP20120505T1 (enExample)
IL (1) IL196181A0 (enExample)
MA (1) MA30607B1 (enExample)
MX (1) MX2009000117A (enExample)
NO (1) NO20090267L (enExample)
PE (1) PE20080997A1 (enExample)
PL (1) PL2049478T3 (enExample)
PT (1) PT2049478E (enExample)
SI (1) SI2049478T1 (enExample)
TW (1) TW200819127A (enExample)
UA (1) UA100227C2 (enExample)
WO (1) WO2008003697A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021201680A1 (en) 2020-03-31 2021-10-07 Hasan Djohan Treatment of hyperinflammatory syndrome

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372955T3 (es) 2006-07-06 2012-01-30 Array Biopharma, Inc. Ciclopenta[d]pirimidinas como inhibidores de la proteína cinasa akt.
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
JP5231411B2 (ja) 2006-07-06 2013-07-10 アレイ バイオファーマ、インコーポレイテッド Ａｋｔプロテインキナーゼ阻害剤としてのジヒドロチエノピリミジン
ATE493418T1 (de) 2006-07-06 2011-01-15 Array Biopharma Inc Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
PL2049478T3 (pl) 2006-07-06 2012-09-28 Glaxo Group Ltd Podstawione N-fenylometylo 5-okso-prolino-2-amidy jako antagoniści receptora P2X7 oraz sposoby ich zastosowania
DE102006047619B4 (de) * 2006-10-09 2008-11-13 Clariant International Limited Verfahren zur Herstellung basischer Fettsäureamide
DE102006047617B4 (de) * 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung basischer (Meth)acrylamide
CA2934202A1 (en) * 2006-10-22 2008-05-02 Idev Technologies, Inc. Methods for securing strand ends and the resulting devices
GB0705882D0 (en) * 2007-03-27 2007-05-02 Glaxo Group Ltd Novel compounds
JP2010522711A (ja) * 2007-03-28 2010-07-08 グラクソ グループ リミテッド Ｐ２ｘ７調節因子としてのピペリジノンカルボキサミド誘導体
JP2010522710A (ja) * 2007-03-29 2010-07-08 グラクソ グループ リミテッド Ｐ２ｘ７調節因子としてのオキサゾリジンおよびモルホリンカルボキサミド誘導体
WO2008119825A2 (en) * 2007-04-03 2008-10-09 Glaxo Group Limited Imidazolidine carboxamide derivatives as p2x7 modulators
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
NZ582692A (en) 2007-07-05 2012-05-25 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US8377937B2 (en) 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2009074518A1 (en) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinations of prolinamide p2x7 modulators with further therapeutic agents
EP2231153A2 (en) * 2007-12-18 2010-09-29 Glaxo Group Limited 5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
GB0724625D0 (en) * 2007-12-18 2008-01-30 Glaxo Group Ltd Novel compounds
WO2009089459A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
CA2711692A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
GB0803729D0 (en) * 2008-02-29 2008-04-09 Ge Healthcare Ltd Imaging the central nervous system
ES2357682T3 (es) 2008-03-25 2011-04-28 Affectis Pharmaceuticals Ag Antagonistas de p2x7r novedosos y su utilización.
DE102008017217A1 (de) * 2008-04-04 2009-10-08 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Amiden aromatischer Carbonsäuren
DE102008017216B4 (de) * 2008-04-04 2013-08-14 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden
DE102008017214B4 (de) * 2008-04-04 2012-02-16 Clariant International Limited Kontinuierliches Verfahren zur Herstellung von Fettsäurealkanolamiden
DE102008017218B4 (de) * 2008-04-04 2011-09-22 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Amiden niederer aliphatischer Carbonsäuren
DE102008017215B4 (de) * 2008-04-04 2012-08-09 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Amiden ethylenisch ungesättigter Carbonsäuren
DE102008017219A1 (de) * 2008-04-04 2009-10-08 Clariant International Ltd. Verfahren zur Herstellung von Amiden in Gegenwart von überhitztem Wasser
DE102008017213B4 (de) * 2008-04-04 2012-08-09 Clariant International Limited Kontinuierliches Verfahren zur Herstellung von Amiden aliphatischer Hydroxycarbonsäuren
WO2010077836A2 (en) * 2009-01-05 2010-07-08 Boehringer Ingelheim International Gmbh Pyrrolidine compounds which modulate the cb2 receptor
DK2243772T3 (da) 2009-04-14 2012-02-13 Affectis Pharmaceuticals Ag Hidtil ukendte P2X7R-antagonister og deres anvendelse
DE102009031059A1 (de) 2009-06-30 2011-01-05 Clariant International Ltd. Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen
DE102009042522A1 (de) 2009-09-22 2011-04-07 Clariant International Ltd. Kontinuierliches Umesterungsverfahren
DE102009042523B4 (de) 2009-09-22 2012-02-16 Clariant International Ltd. Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen
ES2710522T3 (es) 2009-12-08 2019-04-25 Univ Vanderbilt Procedimientos y composiciones para la extracción de venas y autotransplante
CA2792258A1 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
CN102858741A (zh) 2010-05-14 2013-01-02 阿费克蒂斯制药股份公司 制备p2x7r拮抗剂的新方法
DE102010056565A1 (de) 2010-12-30 2012-07-05 Clariant International Ltd. Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere
DE102010056564A1 (de) 2010-12-30 2012-07-05 Clariant International Limited Hydroxylgruppen und Estergruppen tragende Polymere und Verfahren zu ihrer Herstellung
WO2012093101A1 (en) * 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
US20140187533A1 (en) * 2011-03-03 2014-07-03 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
CA2831932A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt and mek inhibitor compounds, and methods of use
RS56759B2 (sr) 2011-04-01 2024-10-31 Genentech Inc Kombinacija akt inhibitor jedinjenja i abiraterona za upotrebu pri terapeutskim tretiranjima
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
ES2574840T3 (es) 2011-07-22 2016-06-22 Actelion Pharmaceuticals Ltd. Derivados de amidas heterocíclicas como antagonistas de receptores p2x7
KR102033190B1 (ko) 2012-01-20 2019-10-16 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 헤테로시클릭 아미드 유도체
US9075975B2 (en) * 2012-02-21 2015-07-07 Andrew Bud Online pseudonym verification and identity validation
EA029644B1 (ru) 2012-12-12 2018-04-30 Идорсиа Фармасьютиклз Лтд Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
CA2891499C (en) 2012-12-18 2021-07-06 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
CA2896790C (en) 2013-01-22 2022-05-10 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
KR102220847B1 (ko) 2013-01-22 2021-02-26 이도르시아 파마슈티컬스 리미티드 Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
FR3026102A1 (fr) * 2014-09-19 2016-03-25 Univ Nice Sophia Antipolis Conjugues d'acide amine-pyridine/pyridinium et leurs utilisations en tant qu'agents biocides
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
JP6884801B2 (ja) 2016-05-31 2021-06-09 カルビスタ・ファーマシューティカルズ・リミテッド 血漿カリクレインインヒビターとしてのピラゾール誘導体
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
DE102016111711A1 (de) * 2016-06-27 2017-12-28 Abb Schweiz Ag Installationsschaltgerät mit einem Gehäuse und mit einer Schraubanschlussklemme
DK3609868T3 (da) * 2017-03-13 2023-11-27 Raqualia Pharma Inc Tetrahydroquinolinderivater som P2X7-receptorantagonister
WO2019006074A1 (en) * 2017-06-28 2019-01-03 Indiana University Research And Technology Corporation PHARMACEUTICAL AGENT THAT RELATES TO THE P2X7 RECEIVER
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
MX2020005168A (es) 2017-11-29 2020-08-20 Kalvista Pharmaceuticals Ltd Formas de dosificacion que contienen un inhibidor calicreina de plasma.
WO2019185868A1 (en) * 2018-03-29 2019-10-03 Centre National De La Recherche Scientifique P2rx7 modulators in therapy
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772601A (en) * 1988-01-25 1988-09-20 Hoechst-Roussel Pharmaceuticals, Inc. 5-Substituted 1-(4-(1-pyrrolidinyl)-2-butynyl)-2-pyrrolidinones, pharmaceutical compositions and use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2651639A (en) * 1951-08-22 1953-09-08 American Cyanamid Co 2-pyrrolidone-5-carboxamide derivatives and methods of preparing the same
FR2273533A1 (fr) * 1974-06-04 1976-01-02 Ferlux Sa Nouveaux derives n-substitues d'acides pyrrolidones-2 carboxyliques-5
JPH0699307B2 (ja) * 1987-08-20 1994-12-07 キッセイ薬品工業株式会社 抗痴呆剤
US6191146B1 (en) 1995-11-13 2001-02-20 Smithkline Beecham Corporation Hemoregulatory compounds
US6054579A (en) * 1997-06-26 2000-04-25 Leukosite, Inc. Synthesis of substituted lactams
SE9704546D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
AU2160900A (en) 1998-12-11 2000-06-26 American Biogenetic Sciences, Inc. Substituted nitrogen heterocyclic compounds and therapeutic uses thereof
CN1215028C (zh) 2002-05-24 2005-08-17 中国科学院上海有机化学研究所 外消旋的联二酚的光学拆分方法
US7288538B2 (en) * 2003-02-20 2007-10-30 Encysive Pharmaceuticals, Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
DE602004018338D1 (de) * 2003-09-22 2009-01-22 Onepharm Res And Dev Gmbh Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
US20080021034A1 (en) * 2006-04-10 2008-01-24 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
WO2008005368A2 (en) * 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
PL2049478T3 (pl) 2006-07-06 2012-09-28 Glaxo Group Ltd Podstawione N-fenylometylo 5-okso-prolino-2-amidy jako antagoniści receptora P2X7 oraz sposoby ich zastosowania
MX2009000801A (es) * 2006-07-22 2009-02-03 Oxagen Ltd Compuestos que tienen actividad antagonista crth2.
CN101621931A (zh) * 2006-11-27 2010-01-06 H.隆德贝克有限公司 杂芳基酰胺衍生物
CN101686680B (zh) * 2007-03-09 2015-12-09 伊沃泰克美国股份有限公司 作为p2x7调节剂的双环杂芳基化合物及其用途
GB0705882D0 (en) * 2007-03-27 2007-05-02 Glaxo Group Ltd Novel compounds
JP2010522711A (ja) * 2007-03-28 2010-07-08 グラクソ グループ リミテッド Ｐ２ｘ７調節因子としてのピペリジノンカルボキサミド誘導体
JP2010522710A (ja) * 2007-03-29 2010-07-08 グラクソ グループ リミテッド Ｐ２ｘ７調節因子としてのオキサゾリジンおよびモルホリンカルボキサミド誘導体
WO2008119825A2 (en) * 2007-04-03 2008-10-09 Glaxo Group Limited Imidazolidine carboxamide derivatives as p2x7 modulators
CN101772498A (zh) * 2007-04-10 2010-07-07 H.隆德贝克有限公司 作为p2x7拮抗剂的杂芳基酰胺类似物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772601A (en) * 1988-01-25 1988-09-20 Hoechst-Roussel Pharmaceuticals, Inc. 5-Substituted 1-(4-(1-pyrrolidinyl)-2-butynyl)-2-pyrrolidinones, pharmaceutical compositions and use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021201680A1 (en) 2020-03-31 2021-10-07 Hasan Djohan Treatment of hyperinflammatory syndrome
EP4582147A2 (en) 2020-03-31 2025-07-09 Remicine IP B.V. Treatment of hyperinflammatory syndrome

Also Published As

Publication number Publication date
KR20140016431A (ko) 2014-02-07
PT2049478E (pt) 2012-07-16
EP2049478A1 (en) 2009-04-22
CR10545A (es) 2009-01-27
JP5283620B2 (ja) 2013-09-04
TW200819127A (en) 2008-05-01
HRP20120505T1 (hr) 2012-07-31
JP2009542595A (ja) 2009-12-03
PL2049478T3 (pl) 2012-09-28
HK1127604A1 (en) 2009-10-02
AU2007271182B2 (en) 2012-03-15
CY1113415T1 (el) 2016-06-22
US20100144829A1 (en) 2010-06-10
SI2049478T1 (sl) 2012-08-31
KR20090028808A (ko) 2009-03-19
US7718693B2 (en) 2010-05-18
US8048907B2 (en) 2011-11-01
WO2008003697A1 (en) 2008-01-10
DK2049478T3 (da) 2012-07-09
EA200970085A1 (ru) 2009-06-30
NO20090267L (no) 2009-03-09
MA30607B1 (fr) 2009-07-01
PE20080997A1 (es) 2008-10-02
CR20140515A (es) 2014-12-01
UA100227C2 (uk) 2012-12-10
AU2007271182A1 (en) 2008-01-10
CA2655675A1 (en) 2008-01-10
EA016076B1 (ru) 2012-01-30
BRPI0714062A2 (pt) 2012-12-18
MX2009000117A (es) 2009-01-23
AR061815A1 (es) 2008-09-24
ES2385505T3 (es) 2012-07-25
IL196181A0 (en) 2009-09-22
EP2049478B1 (en) 2012-05-30
US20080009541A1 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
KR101398264B1 (ko) Ｐ２ｘ７­수용체 길항제로서의 치환된 ｎ­페닐메틸­５­옥소­프롤린­２­아미드 및 그의 사용 방법
ES2795366T3 (es) Compuestos de indol carboxamida útiles como inhibidores de cinasas
CN104781254B (zh) 可作为激酶调节剂的经杂芳基取代的吡啶基化合物
EP2040700B1 (en) N- (phenylmethyl) -2- (1h-pyraz0l-4-yl) acetamide derivatives as p2x7 antagonists for the treatment of pain, inflammation and neurodegeneration
ES2670571T3 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis B
AU2006239929B2 (en) Dipeptidyl peptidase-IV inhibitors
JP7447080B2 (ja) Ｐａｄ４阻害剤としての置換チエノピロール
WO2009074518A1 (en) Combinations of prolinamide p2x7 modulators with further therapeutic agents
JP2010526793A (ja) Ｐ２ｘ７調節因子としてのピラゾール誘導体
JP2009539796A (ja) 新規受容体アンタゴニストおよびそれらの使用方法
JP2010522709A (ja) Ｐ２ｘ７モジュレーターとしてのピロールおよびイソインドールカルボキサミド誘導体
CN101945655A (zh) 作为p2x7调节剂的5-氧代-3-吡咯烷甲酰胺衍生物
TW202019411A (zh) 作為pad4抑制劑之經取代苯并咪唑
JP2010522710A (ja) Ｐ２ｘ７調節因子としてのオキサゾリジンおよびモルホリンカルボキサミド誘導体
CN101952264A (zh) 作为p2x7调节剂的异噻唑烷1,1-二氧化物和四氢-2h-1,2-噻嗪1,1-二氧化物衍生物
US5319096A (en) (1H-indol-1-yl)-2-(amino) acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides, pharmaceutical composition and use
JP2011500767A (ja) Ｐ２ｘ７モジュレータとしての４−ベンゾイル−１−置換ピペラジン−２−オン誘導体
KR20220137657A (ko) Adamts 억제제, 이의 제조 방법 및 의약적 용도
DD279674A5 (de) Verfahren zur herstellung von hydrierten 1-benzooxacycloalkyl-pyridincarbonsaeureverbindungen
CN101511787B (zh) 作为p2x7-受体拮抗剂的被取代的n-苯基甲基-5-氧代-脯氨酸-2-酰胺及它们的使用方法
TW202304875A (zh) 做為Kv1.3鉀SHAKER通道阻斷劑之芳基雜環化合物
HK1127604B (en) Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use
ES2354230T3 (es) Derivados de n-(fenilmetil)-2-(1h-pirazol-4-il)acetamida como antagonistas de p2x7 para el tratamiento del dolor, la inflamación y la neurodegeneración.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170516

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170516

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000